SCHEMBL520225

SCHEMBL520225

CSc1ncc2c(Br)cc(-c3ccccc3)n2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.49
ALDH1A1 P00352 5/20 0.49
HPGD P15428 5/20 0.49
HSD17B10 Q99714 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 6/20 0.45
NPSR1 Q6W5P4 2/20 0.45
POLB P06746 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 1/20 0.38
CKS1B P61024 2/20 0.38
SKP2 Q13309 2/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.34
NTRK1 P04629 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
RXFP1 Q9HBX9 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520651 0.82 PTGS2 (0.40)
SCHEMBL519840 0.77 KDM4E (0.31) KDM4EPOLBRAB9ARXFP1
SCHEMBL520690 0.75 JAK2 (0.42)
SCHEMBL519714 0.74 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3994771 0.71 PLK1 (0.59) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL520341 0.68 KCNH2 (0.41)
SCHEMBL25325595 0.68 LMNA (0.39) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL19222025 0.67 CKS1B (0.31) KDM4EALDH1A1HPGDHSD17B10CKS1B
SCHEMBL25326864 0.66
SCHEMBL463061 0.66 KDM4E (0.74) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 KDM4E 192/4885ALDH1A1 779/4885HPGD 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.